Mylan Acquisition of Agila Receives Approval from India's Foreign Investment Promotion Board and Cabinet Committee on Economic

 Mylan Acquisition of Agila Receives Approval from India's Foreign Investment
          Promotion Board and Cabinet Committee on Economic Affairs

PR Newswire

PITTSBURGH, Sept. 3, 2013

PITTSBURGH, Sept. 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its proposed acquisition of the Agila injectables businesses
from Strides Arcolab Limited (BSE: 532531, NSE: STAR) has received approval
from India's Foreign Investment Promotion Board (FIPB). Subsequently, the
transaction also received approval from the Cabinet Committee on Economic
Affairs (CCEA). The transaction is expected to close in the fourth quarter of
2013, subject to remaining regulatory approvals and certain closing

Mylan CEO Heather Bresch commented, "We are very pleased to have received all
outstanding Indian pre-merger regulatory approvals for the Agila transaction,
especially considering the increased government regulation and oversight with
respect to foreign investment in India. We look forward to completing the
acquisition in the coming months, which we believe will establish Mylan as a
global injectables leader, with a significantly expanded and strengthened
injectables portfolio, pipeline, platform and capabilities."

This press release includes statements that constitute "forward-looking
statements," including with regard to the consummation of the planned
transaction and Mylan's expected future performance. These statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from those
expressed or implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited to:
factors relating to satisfaction of the conditions to the consummation of the
transaction, including remaining regulatory approvals; the impact and effects
of legal or regulatory proceedings, actions or changes; general market
perception of the transaction; uncertainties and matters beyond the control of
management; the ability of the company to achieve the synergies or other
benefits anticipated as a result of the acquisition; any conditions imposed
upon the company in connection with obtaining regulatory approvals; and the
other risks detailed in the company's filings with the Securities and Exchange
Commission. The company undertakes no obligation to update these statements
for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), 724.514.1968; Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.